Table 1.
Baseline clinical characteristics of included patients stratified by RDW
| RDW > 11.5% (n = 48) | RDW ≤ 11.5% (n = 50) | p value | |
|---|---|---|---|
| Age, years | 58.1 ± 14.8 | 54.4 ± 18.8 | 0.289 |
| Gender, female, n (%) | 23 (47.9) | 27 (54.0) | 0.547 |
| Concomitant disorders, n (%) | |||
| Hypertension | 13 (27.1) | 14 (28.0) | 0.919 |
| Diabetes | 2 (4.2) | 2 (4.0) | 1.000 |
| SBP, mmHg | 134.0 ± 24.2 | 133.4 ± 22.9 | 0.902 |
| DBP, mmHg | 82.3 ± 15.6 | 78.2 ± 12.3 | 0.155 |
| Heart rate, bpm | 89.6 ± 14.7 | 89.5 ± 17.8 | 0.980 |
| CRP, mg/L | 10.1 (1.5, 24.1) | 16.4 (4.6, 49.3) | 0.059 |
| Serum creatinine, μmol/L | 63.0 (51.9, 76.2) | 65.5 (52.8, 83.7) | 0.293 |
| eGFR, ml/min/1.73 m2 | 110.2 ± 44.1 | 120.8 ± 39.3 | 0.224 |
| ALT, U/L | 16.0 (10.0, 27.0) | 23.0 (13.0, 43.0) | 0.053 |
| WBC, ×10⁹/L | 6.7 ± 4.5 | 6.0 ± 3.8 | 0.415 |
| Hemoglobin, g/L | 116.9 ± 21.0 | 121.6 ± 15.6 | 0.207 |
| Anemia, n (%) | 22 (45.8) | 15 (30.0) | 0.106 |
| Platelet count, ×10⁹/L | 174.7 ± 75.5 | 162.4 ± 73.6 | 0.415 |
| Creatine kinase, U/L | 70.5 (51.0, 98.5) | 55.5 (36.0, 106.0) | 0.183 |
| Creatine kinase‐MB, U/L | 12.0 (10.0, 17.0) | 11.0 (9.0, 15.5) | 0.456 |
| d‐dimer, mg/L | 0.8 (0.3, 2.2) | 0.5 (0.2, 0.9) | 0.039 |
| Critical cases, n (%) | 30 (62.5) | 13 (26.0) | <0.001 |
| Treatment | |||
| Antibiotic therapy | 37 (77.1) | 46 (92.0) | 0.040 |
| Glucocorticoid therapy | 27 (56.3) | 21 (42.0) | 0.158 |
| Interferon therapy | 22 (45.8) | 14 (28.0) | 0.067 |
| Hospital stay, days | 25 (20, 29) | 25.0 (19.0, 32.8) | 0.536 |
| In‐hospital death | 4 (8.3) | 2 (4.0) | 0.636 |
Abbreviations: ALT, alanine transaminase; CRP, C‐reactive protein; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; RDW, red cell distribution width; SBP, systolic blood pressure; WBC, white blood cell.